Immunohistochemistry analysis of micrometastasis in pretreatment lymph nodes from patients with esophageal cancer

Annals of Thoracic Surgery

Volumn 76, Issue 4, 2003, Pages 996-1000

  Jiao, Xiaolong ^a   Eslami, Afshin ^a   Ioffe, Olga ^a   Kwong, King F ^a   Henry, Michael ^a   Zeng, Qingling ^a   Refaely, Yael ^a   Burrows, Whitney ^a   Gamliel, Ziv ^a   Krasna, Mark J ^a,b   Miller, Joseph I ^c   Cassivi, Stephen D ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KERATIN ANTIBODY; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CORRELATION ANALYSIS; ESOPHAGUS CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; STAINING; THORACOSCOPY; TUMOR BIOPSY; UNDIFFERENTIATED CARCINOMA;

AGED; AGED, 80 AND OVER; BIOPSY; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744233938     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00658-1     Document Type: Article

References (15)

1. Jiao X, Krasna MJ. Clinical significance of micrometastases in lung cancer and esophageal cancer: a new paradigm. Ann Thorac Surg 2002;74:278-84.
2. Godfrey TE, Raja S, Finkelstein SD, Gooding WE, Kelly LA, Luketich JD. Prognostic value of quantitative reverse transcription-polymerase chain reaction in lymph node-negative esophageal cancer patients. Clin Cancer Res 2001;7:4041-8.
3. Komukai S, Nishimaki T, Suzuki T, Kanda T, Kuwabara S, Hatakeyama K. Signifcance of immunohistochemical nodal micrometastasis as a prognostic indicator in potentially curable oesophageal carcinoma. Br J Surg 2002;89:213-9.
4. Krasna MJ, Mao YS, Sonett J, Gamliel Z. The role of thoracoscopic staging of esophageal cancer patients. Eur J Cardiothorac Surg 1999;16(Suppl 1):S31-3.
5. Luketich JD, Kassis ES, Shriver SP, et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg 1998;66:1715-8.
6. Krasna MJ, Mao YS, Sonett J, et al. P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg 1999;68:2021-5.
7. Krasna MJ, Flowers JL, Attar S, McLaughlin J. Combined thoracoscopic/laparoscopic staging of esophageal cancer. J Thorac Cardiovas Surg 1996;111:800-7.
8. Jiao X, Krasna MJ, Sonett J, M, Doyle A, Greenwald B. Pretreatment surgical lymph node staging predicts results of trimodality therapy in esophageal cancer. Eur J Cardiothorac Surg 2001;19:880-6.
9. Mueller JD, Stein HJ, Oyang R, et al. Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophageogastric junction. Cancer 2000;89:1874-82.
10. Kijima F, Natsugoe S, Takao S, et al. Detection and clinical significance of lymph node micrometastasis determined by reverse transcription-polymerase chain reaction in patients with esophageal carcinoma. Oncology 2000;58:38-44.
11. Kassis ES, Nguyen N, Shriver SP, Siegfried JM, Schauer PR, Luketich JD. Detection of occult lymph node metastases in esophageal cancer by minimally invasive staging combined with molecular diagnostic techniques. JSLS 1998;2:331-6.
12. Hosch S, Kraus J, Scheunemann P, et al. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res 2000;60:6836-40.
13. Shimoji H, Miyazato H, Nakachi A, et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 2000;13:185-90.
14. Harpole DH, To K, Moore-Hoshi MB, Toloza EM, D'Amico TA. Evaluation of chemotherapy resistance markers in patients with stage III non-small cell lung cancer. 48th Annual meeting of the Southern Thoracic Surgical Association, San Antonio, TX, Nov 8-10, 2001.
15. Pollack JR, Van De Rijn M, Bostein D. Challenges in developing a molecular characterization of cancer. Semin Oncol 2002;29:280-5.